Vir Biotechnology (VIR) PT Slashed to $45 at Needham & Company on sotrovimab Issues
Tweet Send to a Friend
Needham & Company analyst Joseph Stringer lowered the price target on Vir Biotechnology (NASDAQ: VIR) to $45.00 (from $80.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
